Shahina Jafry, MD
Psychiatry · Rockford, ILNPI 1053383737
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Alkermes, Inc. accounts for 62.8% of it on its own, with 32 other manufacturers making up the rest. Among psychiatry clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,222 payments — averaging $67.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$51K
- E.r. Squibb & Sons, L.L.C.$13K
- Otsuka America Pharmaceutical, Inc.$2K
- Lundbeck LLC$2K
- AbbVie$2K
- Neurocrine Biosciences, Inc.$2K
- plus $10K from 27 others
What the payments were for
- Consulting fees$6,5508%
- Speaking & faculty fees$46,57557%
- Travel & lodging$6,4158%
- Food & beverage$22,24727%
- Education$2020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$81,988 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 253 | $711,487 |
| IngrezzaValbenazine Tosylate | 39 | $329,996 |
| AristadaAripiprazole Lauroxil | 86 | $303,589 |
| Invega TrinzaPaliperidone Palmitate | 20 | $144,724 |
| Abilify MaintenaAripiprazole | 47 | $124,675 |
| VraylarCariprazine Hcl | 88 | $122,994 |
| RexultiBrexpiprazole | 32 | $44,967 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $28,724 |
| FanaptIloperidone | 11 | $28,462 |
| Aripiprazole | 235 | $28,310 |
| Lurasidone Hcl | 103 | $26,399 |
| Quetiapine Fumarate | 884 | $12,830 |
| Hydroxyzine Hcl | 831 | $11,586 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $11,414 |
| Ziprasidone Hcl | 192 | $10,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $1,024 | $856,211273 claims |
| Alkermes, Inc.Aristada, Lybalvi | $51,495 | $332,314104 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,545 | $329,99639 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $2,203 | $169,64279 claims |
| AbbVieVraylar | $1,814 | $122,99488 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,474 | $28,46211 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,079 | $11,41413 claims |
| MerckBelsomra | $75 | $4,84111 claims |
| Almatica Pharma LLCSertraline Hcl | $177 | $2,779216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Rockford
- Jose MontesRockford$882K
- Babatunde OgundipeRockford$37K
- Uma SrivastavaRockford$23K
- Raymond GarciaRockford$16K
- Michael FeldNorthbrook$1.1M
- Mitchell GlaserChicago$752K
- Roukan JazayerliOrland Park$597K
- Ming XuBourbonnais$505K
- Peter WeidenChicago$440K
- Michelle DeesChicago$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.